



# 37th Annual Medical & Scientific Conference

## Hyperlipidaemia | National and international perspectives

Wednesday 10 - Friday 12 July 2024 | University of Warwick (Coventry)

### Programme

British Dietetic Association - endorsement approved


CPD pending via the Royal Colleges of Physicians

## Tuesday 9 July

Time	Session duration		Topic	Venue location
16:00 – 18:30	90	Invited participants only CPD not applicable	<b>HEART UK Board meeting</b> Chaired by: <a href="#">Jules Payne</a> + <a href="#">Pete Green</a>	Radcliffe House - Rad space 12
18:00 - 22:00	240		EXHIBITION BUILD	Oculus foyer

## Wednesday 10 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:30			Registration opens		Oculus foyer
08:00 - 09:30	90	Invited participants only CPD not applicable	<b>HEART UK MS&amp;R Committee meeting</b> Chaired by: <a href="#">Prof Handrean Soran</a>		Oculus room OC 1.01 - 1st floor
09:45 - 10:45	60	Invited participants only CPD not applicable	<b>Lipid Interest group meeting</b> Chaired by: <a href="#">Ms Alison Pottle</a>		Oculus room OC 0.02 - grnd floor
11:00 - 12:20	70	<b>Livestream</b>	<b>SESSION ONE   Welcome + International Perspectives</b>		Oculus LT 1.05 - 1st floor
11:00 - 11:10	10	<b>Livestream</b>	<b>Chairman's Welcome</b> <a href="#">Dr Peter Green</a> (Chair, HEART UK)		Oculus LT 1.05 - 1st floor
			Co-chairs: <a href="#">Dr Nigel Capps</a> + <a href="#">Dr Pete Green</a>		
11:10 - 11:40	30	<b>Livestream</b>	<b>Plenary speaker</b> <b>Dyslipidemia and Cardiovascular Disease: A Global Perspective</b> Implementable policies to increase awareness, diagnostic, access and adherence to treatments on a global scale. <a href="#">Dr Jean-Luc Eiselé</a> (Geneva, SWITZERLAND)		

11:40 - 12:10	30	Livestream	<p><b>Plenary speaker</b>  <b>International challenges for cardiovascular prevention around lipids. Results of the INTERASPIRE study in 14 countries across all 6 WHO regions</b>  Lipids management worldwide falls well below guideline standards, with enormous heterogeneity in outcomes between countries  <b>Prof Kornelia Kotseva</b> (London, UK)</p>		
12:10 - 12:20	10		Group discussion		
12:20 - 13:00	40		<b>Lunch</b>		Oculus foyer
13:00 - 14:00	60	Livestream	<p><b>SESSION TWO   NICE v European Guidelines</b>  Organised by: <b>Dev Datta + Jules Payne</b>  Chaired by: <b>Dr Jai Cegla</b></p>		
13:00 - 13:25	25		<p><b>Plenary speaker</b>  <b>NICE v other guidelines</b>  <b>Prof Riyaz Patel</b> (Professor of Cardiology, UCL, London, UK)</p>		Oculus LT 1.05 - 1st floor
13:25 - 13:50	25		<p><b>Plenary speaker</b>  <b>LDL-C calculation – What comes next after Friedewald?</b>  Describing recent advances in low-density lipoproteins and their diagnostic and therapeutic implications.  <b>Dr Alan Remaley</b> (Senior Investigator, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA)</p>		Oculus LT 1.05 - 1st floor
13:50 - 14:00	10		Group discussion		
14:00 - 14:30	30		Refreshments   Networking   Exhibition		Oculus foyer
14:30 - 15:30	60	Livestream	<p><b>SESSION THREE   Joint session with BIHS</b>  Co-Chairs: BIHS rep TBC + <b>Prof Dev Datta</b></p>		
14:30 - 14:55	25	<p><b>Optimal treatment in Hypertension</b>  <b>Dr Kazem Rahimi</b> (Oxford, UK)</p>	Oculus LT 1.05 - 1st floor		
14:55 - 15:20	25	<p><b>How should I manage hypertension in my clinic</b>  <b>Dr Pankaj Gupta</b> (Consultant, Department of Metabolic Medicine and Chemical Pathology, University Hospitals Leicester)</p>	Oculus LT 1.05 - 1st floor		
15:20 - 15:30	10		Discussion		
15:30 - 16:00	30		Refreshments   Networking   Exhibition		Oculus foyer
16:00 - 16:40	40	Livestream	<p><b>Symposia session 1</b>  <i>Programme under development by the sponsor.</i>  <b>Sponsored by Sanofi</b></p>		Oculus LT 1.05 - 1st floor
16:40 - 16:50	10		Changeover		
16:50 - 17:30	40	Livestream	<p><b>Symposia session 2</b>  <i>Programme under development by the sponsor.</i>  <b>Sponsored by Daiichi-Sankyo</b></p>		Oculus LT 1.05 - 1st floor
17:30 - 17:40	10		Comfort break		
17:40 - 18:40		Livestream	<p><b>Managing hypertriglyceridaemia: What is new?</b>  Organised by: <b>Handrean Soran</b>  <i>Programme under development</i></p>		Oculus LT 1.05 - 1st floor

18:40 - 19:10	30	In person only	<b>FH and allied health professional networking session</b> This is a networking session where FH nurses and allied health care professionals working with familial hypercholesterolaemia can meet and share best practice, information on current projects (national or local) or ask for advice about any issues or barriers they are experiencing in their work. We are a supportive group and welcome all newcomers to the field of FH work. Hosted by: <a href="#">Ms Lisa Gritzmacher</a> <i>CPD is not applicable to this session</i>	Oculus - 0.02 grnd floor
19:10 - 20:00	45	In person only	<b>Spotlight on posters - meet the authors</b> An informal session where the audience can meet all the poster authors to discuss their work. This session is unjudged. <i>See poster listing at end of programme</i>	Oculus - 1st floor landing
19:00 - 21:30	180		<b>Welcome and buffet reception</b>	Oculus foyer
19:30:00			Chairman's welcome   <a href="#">Dr Pete Green</a> Premium sponsor welcome	
21:30:00			Presentation of the Rianna Wingett award by <a href="#">Dr Pete Green</a> Evening ends	

## Thursday 11 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:00 - 09:00	60	Invited participants only CPD not applicable	<b>Healthcare committee meeting</b> Chaired by: <a href="#">Ms Michaela Nuttall</a> <i>Invited attendance only - CPD is not applicable</i>		Oculus room OC 1.01 - 1st floor
08:30			Registration opens		Oculus foyer
08:30 - 09:10	50		Refreshments   Networking   Exhibition		Oculus foyer
09:10 - 09:15	5		Opening remarks <a href="#">Prof Dev Datta</a>		Oculus LT 1.05 - 1st floor
	70	Livestream	<b>SESSION FOUR   Women and CVD</b>		
			Organised by: <a href="#">Tina Khan</a> + <a href="#">Lorraine Priestley-Barnham</a> Co-chairs: <a href="#">Dr Tina Khan</a> + <a href="#">Prof Gerald Watts</a>		
09:15 - 09:35	20		<b>Plenary speaker</b> Empowering change: The EAS call to action on women, lipids and CVD <a href="#">Prof Jeanine Roeters van Lennepe</a> (HOLLAND)		Oculus LT 1.05 - 1st floor
09:35 - 09:55	20		<b>Plenary speaker</b> Cardiovascular risk management during puberty, conception, pregnancy and beyond <a href="#">Dr Antonio de' Marvao</a> (London, UK)		Oculus LT 1.05 - 1st floor
09:55 - 10:15	20		<b>Plenary speaker</b> Coronary prevention and lipid management during menopause and INOCA <a href="#">Prof Peter Collins</a> (London, UK)		Oculus LT 1.05 - 1st floor
10:15 - 10:25	10		Panel discussion and Q&A		
10:25 - 10:55	30		Refreshments   Networking   Exhibition		Oculus ground floor
	75	Livestream	<b>SESSION FIVE   Paeds</b>		
10:55 - 11:05			Organised by: <a href="#">Tina Khan</a> + <a href="#">Lorraine Priestley-Barnham</a>		Oculus LT 1.05 - 1st floor

			Co-chairs: <a href="#">Ms Lorraine Priestley-Barnham</a> + <a href="#">Dr Uma Ramaswami</a>	
10:55 - 11:15	20		<b>Unlocking the Future; Familial Hypercholesterolaemia and the Newborn Genomes Programme</b> What are the potential benefit and possible drawbacks of identifying families with FH by whole genome sequencing of a newborn baby? <a href="#">Prof Steve Humphries</a> (London, UK)	
11:15 - 11:35	20		<b>Navigating paediatric Homozygous FH management</b> <a href="#">Dr Mike Champion</a> , Consultant Paediatrician & Clinical Lead, Inherited Metabolic Conditions, Evelina, London, UK	
11:35 - 11:55	20		<b>Challenges in Paediatric Homozygous FH Management, Insights from Sheffield</b> A case study based presentation highlighting the challenges faced in managing children with Homozygous Familial Hypercholesterolaemia. <a href="#">Miss Nichola Cowie</a> (Senior Clinical Nurse Specialist in Metabolic Medicine, Sheffield Children's Hospital, Sheffield, UK)	
11:55 - 12:10	15		Panel discussion and Q&A	
12:10 - 12:45	35	Livestream	<b>Paeds sponsored session</b> <i>Programme under development by the sponsor.</i> <b>Sponsored by Ultragenyx</b>	Oculus LT 1.05 - 1st floor
12:45 - 13:35	50		Lunch   Networking   Exhibition	Oculus ground floor
12:45 - 13:35	50	Invited participants only CPD not applicable	<b>Simon Broome committee meeting</b> Chaired by: <a href="#">Dr Nigel Capps</a>	Oculus room OC 1.01 - 1st floor
13:00 - 13:10	10	In person only	<b>Premium sponsor "Meet the expert"</b> Hosted on the Amgen stand	Amgen stand
13:05 - 13:35	30	In person only	<b>Lunch and Learn</b> <b>What is the changing role of the pharmacist?</b> Organised by: <a href="#">Peter Penson</a> <i>CPD is not applicable to this session</i>	Oculus mtg OC 0.02 - grnd floor
13:35 - 14:45	70	Livestream	<b>SESSION SIX   Diet and Lifestyle</b> Organised and Chaired by: <a href="#">Lynne Garton</a> (Dietetic Adviser at HEART UK)	Oculus LT 1.05 - 1st floor
			<b>Session 1:</b> <b>Panel discussion on the dietary management of metabolic lipid conditions</b> <a href="#">Dr Alan Flanagan</a> , University of Surrey, UK <a href="#">Dr Kofi Antwi</a> , Specialist Registrar, University of Bristol, UK <a href="#">Mr Simon Tapley</a> , Specialist Adult Dietitian for Inherited Metabolic Disorders, University of Bristol, UK	
			<b>Session 2:</b> <b>Charting success: an update on HEART UK's Diet Quizzes to support the dietary management of cholesterol</b> Presenting the results from HEART UK's newly updated online dietary assessment tool. The revised diet quizzes provide consumers with tailored and realistic dietary advice, encouraging them to review their diet regularly. <a href="#">Ms Elphee Medici</a> , Nutrition Consultant, UK	
14:45 - 15:20	35		Refreshments   Networking   Exhibition	Oculus foyer
15:20 - 16:35	75	Livestream	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Medical &amp; Scientific</b> Oculus LT 1.05 - 1st floor	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Primary &amp; Healthcare</b> Oculus LT 0.03 - ground floor

			Co-chairs: Pete Carey (TBC) + Paul Downie (TBC)	Co-chairs: <a href="#">Ms Michaela Nuttall</a> + <a href="#">Dr Pete Green</a>	
15:20 - 15:30	10		FC 1	FC 6	
			Genetic Landscape of Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) in United Kingdom	Challenges and opportunities for identifying people with Familial Hypercholesterolaemia in the UK: Evidence from the National FH PASS database	
			<a href="#">Bilal Bashir</a> (University of Manchester, UK)	<a href="#">Edward Cox</a> (University of York, UK)	
15:30 - 15:35	5		Discussion	Discussion	
15:35 - 15:45	10		FC 2	FC 7	
			The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): Nine-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)	Bempedoic acid: real-world efficacy and tolerability in lipid clinics across three UK Centres	
			<a href="#">Jaimini Cegla</a> (Imperial College Healthcare NHS Trust, London, UK)	<a href="#">Agnieszka Jakubowska</a> (East and North Hertfordshire NHS Trust, Stevenage, UK)	
15:45 - 15:50	5		Discussion	Discussion	
15:50 - 16:00	10		FC 3	FC 8	
			Variants in LPA are associated with mutation-negative Familial Hypercholesterolaemia: whole genome sequencing analysis in the 100,000 Genomes Project	Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of patient-level LDL-C reduction, fat soluble vitamins, lipoproteins and patient maturation from the APH-19 study	
			<a href="#">Marta Futema</a> (University College London, UK)	<a href="#">Zsuzsanna Tamas</a> (Chiesi Pharmaceuticals, Bois-Colombes, France)	
16:00 - 16:05	5		Discussion	Discussion	
16:05 - 16:15	10		FC 4	FC 9	
			HMGCoAR autoantibodies: hidden in plain sight?	Hypertriglyceridaemia and Cardiovascular Autonomic Function in Patients Without Diabetes Mellitus	
			<a href="#">Gavin Mercer-Smith</a> (Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK)	<a href="#">Bilal Bashir</a> (University of Manchester, UK)	
16:15 - 16:25	5		Discussion	Discussion	
16:25 - 16:30	10		FC 5	FC 10	
			Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials	Clinical Service Quality and Unmet Needs in Homozygous Familial Hypercholesterolaemia Patients: Insights from UK Tertiary Centres	
			<a href="#">Alexis Llewellyn</a> (University of York, UK)	<a href="#">Raabya Pasha</a> (University of Manchester, UK)	
16:30 - 16:35	5		Discussion	Discussion	
16:35 - 17:05	30		Refreshments   Networking   Exhibition		Oculus foyer
	60	<a href="#">Livestream</a>	<b>SESSION EIGHT</b>		
			Chair: <a href="#">Prof Handrean Soran</a>		
			<b>Keynote Myant lecture:</b> <b>An International Perspective on Models of Care for FH</b> International experience on gaps in care for FH will be reviewed and clinical and implementation guidance for closing these gaps will be presented based on contemporary evidence.		
17:05 - 18:05	60		<a href="#">Prof Gerald Watts</a> (Perth, AUSTRALIA)		Oculus LT 1.05 - 1st floor
18:05 - 18:10	5		Day two closing remarks		
19:00 - 19:30			Pre dinner drinks reception		Panorama Suite (2nd floor, Rootes Building)
19:30 - 23:30			Conference dinner		Panorama Suite (2nd floor, Rootes Building)

## Friday 12 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (Bluebell House residential guests only)		Rootes Building - 1st floor restaurant
08:30			Registration opens		Oculus foyer
08:00 - 09:00		Invited participants only CPD not applicable	<b>Apheresis Working Group committee meeting</b> Chaired by: <a href="#">Prof Dev Datta</a>		Oculus room OC 0.02 - grnd floor
08:30 - 09:30	60		Refreshments   Networking   Exhibition		Oculus foyer
08:50 - 09:50	60	In person only	<b>Spotlight on posters session</b>		Oculus first floor landing
			Moderated only		
			Judges   <a href="#">Dr Nigel Capps</a> , <a href="#">Dr Tina Khan</a> , <a href="#">Dr Andreas Tridima</a> , <a href="#">Prof Gerald Watts</a>		
		MP 01	<b>Using cardiovascular and imaging biomarkers to identify patients with familial hypercholesterolaemia</b> <a href="#">Wiaam Al-Hasani</a> (Guy's & St Thomas Hospitals, London, UK)		
		MP 02	<b>A tale of 2 pregnancies: the biochemical trends, medical management, and outcomes of hypertriglyceridemia in pregnancy secondary to multi-factorial chylomicronaemia syndrome (MCS) and extreme ketogenic/carnivorous diet</b> <a href="#">Nathan Cantley</a> (Bristol Royal Infirmary, University Hospitals of Bristol and Weston NHSFT, UK)		
		MP 03	<b>A New Diagnosis of Familial Chylomicronaemia Syndrome in a 15-Year-Old Male: From Lab to Clinic</b> <a href="#">Samir Elgeray</a> (Nottingham University Hospitals NHS Trust, Nottingham, UK)		
		MP 04	<b>Target gene selection and design of precise base editing therapies for atherosclerotic cardiovascular disease</b> <a href="#">Fred Fiedorek</a> (Verve Therapeutics, Boston, USA)		
		MP 05	<b>Free Circulating PCSK9 is Positively Correlated with Body Mass Index in Healthy Volunteers</b> <a href="#">Anoushka Kamath</a> (University of Manchester, UK)		
		MP 06	<b>Ketogenic diet and extreme hypercholesterolaemia: A case of polygenic hypercholesterolemia</b> <a href="#">Tina Mazaheri</a> (Imperial College Healthcare NHSFT, London, UK)		
		MP 07	<b>Real-world efficacy and side effect profile of bempedoic acid in a tertiary centre lipid clinic</b> <a href="#">Kian Parsapour Moghadam</a> (Imperial College London, UK)		
		MP 08	<b>Statin Treatment in Type 1 Diabetes is Not Associated with Diabetic Peripheral Neuropathy</b> <a href="#">Raabya Pasha</a> (University of Manchester, UK)		
		MP 09	<b>Update on the United Kingdom Paediatric FH Register: Working towards new evidence on when children with Familial Hypercholesterolaemia should start lipid lowering therapies</b> <a href="#">Laila Tata</a> (University of Nottingham, UK)		
		MP 10	<b>Ketogenic Diet – a culinary delight but is there a cautionary tale?</b> <a href="#">Rajalakshmi Valaiyapathi</a> (King's College Hospital NHSFT, London, UK)		
09:50 - 10:00	10		Comfort break		
	85		<b>SESSION NINE - sponsored symposia</b>		
			<b>Symposia session 3</b> <i>Programme under development by the sponsor.</i> <b>Sponsored by Amarin</b>		
10:00 - 10:40	40	<b>Livestream</b>			Oculus LT 1.05 - 1st floor
10:40 - 10:50	5		Changeover		

10:50 - 11:30	40	Livestream	<b>Symposia session 4</b> Programme under development by the sponsor. <b>Sponsored by Amgen</b>	Oculus LT 1.05 - 1st floor
11:30 - 11:50	20		Refreshments   Networking   Exhibition	Oculus foyer
		Livestream	<b>SESSION TEN</b>	
11:50 - 13:10	80		<b>Clinical Lipidology Live</b> Live patient case studies and discussion Facilitator: <b>Prof Dev Datta</b> Panel members: Case study authors in audience	Oculus LT 1.05 - 1st floor
13:10 - 13:20	10	Livestream	<b>Presentation of prizes and awards</b> <b>Closing remarks</b> <b>Dr Pete Green</b> (Chair - HEART UK)	
			<b>Unmoderated posters</b>	
			Networking session   Wed 10 July   19:10-20:00 hrs	
			P11 <b>Assessing the real-world efficacy of inclisiran: Findings from a single-centre study</b> <b>Rehan Aftab</b> (Imperial College London, UK)	
			P12 <b>Transforming lipid pathway in primary care through system partnership and virtual lipid multidisciplinary team approach</b> <b>Pei-Theng Aizlewood</b> (West Yorkshire Integrated Care Board, Yorkshire, UK)	
			P13 <b>A Systematic Approach to Lipid-Lowering Treatment Intensification in a Primary Care Population with Cardiovascular Disease</b> <b>Nicholas Ashley</b> (Royal United Hospital, Bath, UK)	
			P14 <b>Supporting Primary Care with Lipid Optimisation - The impact of a virtual integrated lipid optimisation service</b> <b>Alia Awani</b> (Leeds Teaching Hospitals NHS Trust, Leeds, UK)	
			P15 <b>A south London cardiovascular disease (CVD) prevention fellowship to reduce CVD risk and upskill primary care clinicians</b> <b>Nathan Beencke</b> (Heath Innovation Network, London, UK)	
			P16 <b>Integrated lipidology service for secondary prevention (2-year funded project)</b> <b>Mo Bullen</b> (Lincolnshire Community Health Services#, Lincoln, UK)	
			P17 <b>Lipid Optimisation for Acute Stroke and TIA patients: Benchmarking Against the AHSN Pathway</b> <b>Alexandra Cann</b> (Imperial College Healthcare NHSFT, London, UK)	
			P18 <b>"Direct to Test" – Optimising Lipid Clinic Resources for Primary Care Referrals for Familial Hypercholesterolaemia Genetic Testing</b> <b>Peter Carey</b> (South Tyneside and Sunderland NHSFT, Sunderland, UK)	
			P19 <b>The use of Inclisiran in a patient undergoing lipoprotein apheresis and an observed lowering effect on Lp(a)</b> <b>Claire Chalwin</b> (Royal Brompton & Harefield Hospitals, London, UK)	
			P20 <b>Improving cardiovascular disease outcomes of CORE2oPLUS patient population using an integrated outreach multidisciplinary team community hub model</b> <b>James Chapman</b> (South East Leeds GP Federation Group, Leeds, UK)	
			P21 <b>The characterisation of LDL-C target achievement in patients attending diabetic foot clinic</b> <b>Qaisar Farooq</b> (Heartlands Hospital, Birmingham, UK)	
			P22 <b>Systematic Opportunistic Lipid Optimisation (SOLO) – an initiative to opportunistically improve secondary prevention for medical inpatients</b> <b>Jonathan Fenwick</b> (Gateshead Health NHSFT, Gateshead, UK)	
			P23 <b>Atherosclerotic cardiovascular disease residual risk reduction – an innovative cardio-renal-metabolic multidisciplinary team approach to secondary prevention</b>	

	<a href="#">Jonathan Fenwick</a> (Gateshead Health NHSFT, Gateshead, UK)	
P24	<b>West Midlands Familial Hypercholesterolaemia Service - Cascading an innovative model of delivery</b>	
	<a href="#">Elaine George</a> (Queen Elizabeth Hospital, Birmingham, UK)	
P25	<b>Out-of-surgery screening programme with innovative smartphone-enabled digital CVD risk assessment tool holds promise to improve CVD outcomes</b>	
	<a href="#">Vladimir Gubala</a> (Vital Signs Solutions, Cambridge, UK)	
P26	<b>Barts Health Quality Improvement Project: Familial Hypercholesterolaemia Genetic Testing – Can Commercial Providers Support Clinical Services to Meet Targets?</b>	
	<a href="#">Cararina Guerreiro</a> (St Bartholomew's Hospital, London, UK)	
P27	<b>Addressing Cardiovascular Health Inequity: A Multidisciplinary Programme for Optimising Lipid Management in North East London</b>	
	<a href="#">Nadya Hamed</a> (Barts Health NHS Trust, London, UK)	
P28	<b>Identifying enablers for Pharmacists to demonstrate their competence to provide high-quality, consistent Familial Hypercholesterolaemia gene testing</b>	
	<a href="#">Nadya Hamed</a> (Barts Health NHS Trust, London, UK)	
P29	<b>An audit of the impact of clinical biochemists in the lipid clinic</b>	
	<a href="#">Shonagh Haslam</a> (Lancashire Teaching Hospitals NHS Trust, Preston, UK)	
P30	<b>Introduction of a Lipid MDT to improve outcomes for individuals attending Cardiac Rehabilitation in Aneurin Bevan University Health Board</b>	
	<a href="#">Sarah Howard</a> (Cardiac Rehabilitation Aneurin Bevan University Health Board (ABUHB), Abergavenny, UK)	
P31	<b>Implementing Novel Therapies and Pathways at scale across a Primary Care Network using Clinical Pharmacists</b>	
	<a href="#">Mamoud Khodadi</a> (Affinity Care PCN, Bradford, UK)	
P32	<b>Case study: liver transplantation for a case of homozygous familial hypercholesterolemia with subsequent evolocumab therapy</b>	
	<a href="#">Lakshmi Lakkineni</a> (Imperial College London, UK)	
P33	<b>Assessing polygenic hypercholesterolaemia and raised lipoprotein(a) in a diverse multi-ethnic cohort</b>	
	<a href="#">Rajalakshmi Valaiyapathi</a> (King's College Hospital NHSFT, London, UK)	
P34	<b>Eicosapentaenoic acid (EPA) inhibits lipoprotein(a) [Lp(a)] with higher rates of oxidation compared to non-modified low-density lipoprotein (LDL) in vitro</b>	
	<a href="#">Preston Mason</a> (Brigham & Women's Hospital< Boston, USA)	
P35	<b>Laboratory lipid service provision across Scotland. A combined survey through the Scotland Clinical Biochemistry Network (SCBN) Lipid subgroup and Association for Laboratory Medicine Scotland Audit Group</b>	
	<a href="#">Karen Mitchell</a> (Aberdeen Royal Infirmary, UK)	
P36	<b>"We did it! I am the first person in my family to reach retirement age". 21 Years of Lipoprotein Apheresis – A Case Study</b>	
	<a href="#">Samantha Mower</a> (Royal Brompton & Harefield Hospitals, London, UK)	
P37	<b>Exploring clinical and genetic variability in familial chylomicronaemia syndrome: A case series study</b>	
	<a href="#">Madhavi Nallagonda</a> (Imperial College Healthcare NHSFT, London, UK)	
P38	<b>Cascade Screening in Familial Hypercholesterolaemia: A simple solution, or is it?</b>	
	<a href="#">James Nurse</a> (University of Southampton, UK)	
P39	<b>PCSK9 inhibitors and achievement of lipid targets: An audit-based evaluation</b>	
	<a href="#">Amal Owaydah</a> (University Hospital of North Durham, UK)	
P40	<b>The effect of exercise training on blood lipids: A systematic review and meta-regression analysis.</b>	
	<a href="#">Neil Smart</a> (University of New England, Armidale, Australia)	



P41	<b>Comparison of package insert vs. real world safety data from branded icosapent ethyl users: a select analysis utilizing MarketScan data</b>	
	<a href="#">Handrean Soran</a> (University of Manchester, UK)	
P42	<b>Audit on heterozygous Familial Hypercholesterolemia within Leeds Teaching Hospitals Trust (LTHT)</b>	
	<a href="#">Ekaahh Sumithran</a> (University of Leeds, UK)	
P43	<b>Cross-sector, multi-disciplinary collaboration for lipid optimisation – a promising model of care in Staffordshire and Stoke-on-Trent</b>	
	<a href="#">Helen Wrightson</a> (University Hospitals of North Midlands, Stoke-on-Trent, UK)	